Use of serological proteomic methods to find biomarkers associated with breast cancer

New technologies for the detection and therapy of early stage breast cancer are urgently needed. Pathological changes in breast might be reflected in proteomic patterns in serum. A proteomic tool was used to identify proteomic patterns in serum that distinguishes neoplastic from non‐neoplastic disease within the breast. Preliminary results derived from the serum analysis from 54 unaffected women and 76 petients with breast cancer were analyzed by two‐dimensional (2‐D) electrophoresis and matrix‐assisted laser desorption/ionization‐time of flight mass spectrometry, HSP27 was found up‐regulated while14‐3‐3 sigma was down‐regulated in the serum of breast cancer patients. The two protein biomarkers were then used to classify an independent set of 104 masked serum samples. The results showed that the protein pattern on 2‐D gels can completely segregate the serum of breast cancer from non‐cancer. The discriminatory pattern correctly identified all 69 breast cancer cases in the masked set. Of the 35 cases of non‐malignant disease, 34 were recognized as non‐cancer. These findings justify a prospective population‐based assessment of proteomic technology as a screening or diagnostic tool for breast cancer in high‐risk and general populations. These two protein biomarkers could also be used as targets for further study in drug design and breast cancer therapy.